Tekmira Ebola drug gets regulator modification for possible human use
Aug 7 (Reuters) - Tekmira Pharmaceutical Corp said on Thursday that the U.S. Food and Drug Administration had modified its clinical hold status on Tekmira's experimental Ebola treatment to enable its potential use in humans infected with the virus.
The FDA told Burnaby, British Columbia-based Tekmira that it had modified the full clinical hold on the drug to a partial clinical hold, the company said in a statement. (Reporting by Rod Nickel in Winnipeg, Manitoba; Editing by Bernard Orr)
© Thomson Reuters 2017 All rights reserved.